非肝硬化代谢功能障碍相关脂肪性肝病患者纵向生物标志物与主要不良肝脏结局的关联
该队列纳入1974至2019年1260例非肝硬化代谢功能障碍相关脂肪性肝病(MASLD)患者,中位随访12.2年,111例(8.8%)发生主要不良肝脏结局(MALO)。联合模型显示,任一时刻纤维化-4评分升高、天冬氨酸氨基转移酶升高及血小板计数降低与MALO风险增加相关,而这些标志物的变化速率与风险无关。
要点
- 中位随访12.2年,1260例非肝硬化MASLD患者中111例(8.8%)发生MALO。
- 任一时刻纤维化-4评分升高与MALO风险增加相关(HR 2.60,95%CI 1.89-3.50)。
- 任一时刻天冬氨酸氨基转移酶升高(HR 2.69,95%CI 2.57-3.05)及血小板计数降低(HR 0.93,95%CI 0.90-0.97)与MALO风险增加相关。
核心结论
- 除基线非侵入性生物标志物(纤维化-4评分、天冬氨酸氨基转移酶、血小板)外,监测其随时间的最新值与未来MALO风险密切相关,而变化速率可能不重要。
研究设计与样本
- 分析1974至2019年1260例非肝硬化MASLD患者队列(71.7%经活检),基线及随访数据来自病历。
- MALO通过病历及链接国家登记确定至2020年底,采用联合建模量化生物标志物轨迹与MALO风险的关联。
主要发现
- MASLD诊断中位年龄52岁(IQR 39-60),男性占59%。
- 中位随访12.2年,111例(8.8%)发生MALO。
- 任一时刻纤维化-4评分升高(HR 2.60,95%CI 1.89-3.50)、天冬氨酸氨基转移酶升高(HR 2.69,95%CI 2.57-3.05)及血小板计数降低(HR 0.93,95%CI 0.90-0.97)与MALO风险增加相关。
- 这些生物标志物的变化速率与MALO风险无关联。
临床怎么用
- 作者认为,除基线测量外,监测纤维化-4评分、天冬氨酸氨基转移酶和血小板随时间的最新值很重要,因其与未来MALO风险密切相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Noninvasive biomarkers provide prognostic information for the development of major adverse liver outcomes (MALOs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the predictive value of longitudinal biomarker measurements has not been evaluated. We assessed whether changes in biomarkers could predict incident MALO in MASLD. APPROACH AND RESULTS: We analyzed a cohort of 1260 patients (71.7% on biopsy) with non-cirrhotic MASLD between 1974 and 2019. Data at baseline and follow-up visits were obtained from medical charts. MALO was determined through medical charts and linkage to national registers until the end of 2020. A joint modeling approach was used to quantify the associations between the trajectory of biomarkers and the risk of MALO. MASLD was diagnosed at a median age of 52 years (IQR: 39-60), and 59% were male. During a median follow-up of 12.2 years, 111 (8.8%) patients developed MALO. The joint modeling showed that an elevated fibrosis-4 score (HR: 2.60, 95% CI: 1.89-3.50), aspartate aminotransferase (HR: 2.69, 95% CI: 2.57-3.05), and lower platelet count (HR: 0.93, 95% CI: 0.90-0.97) at any time point were associated with an increased risk of MALO, whereas the rate of change in these biomarkers had no association with this risk. CONCLUSIONS: In addition to baseline measurements of noninvasive biomarkers such as fibrosis-4 score, aspartate aminotransferase, and platelets taken at MASLD diagnosis, monitoring their values over time is important, as the latest value of these biomarkers is closely associated with the risk of future MALO. The rate of change may not be as important.
引用
- Shang Y, Akbari C, Dodd M, et al. Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024. PMID: 39110990. doi:10.1097/HEP.0000000000001045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。